Holen Sie sich die Stockscreener-App
7.5885
3.81%
-0.2815
Schlusskurs vom Vortag:
$7.87
Offen:
$7.74
24-Stunden-Volumen:
105.57K
Relative Volume:
0.38
Marktkapitalisierung:
$188.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
-36.54
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
-15.89%
1M Leistung:
-14.94%
6M Leistung:
-20.82%
1J Leistung:
-24.68%
1-Tages-Spanne:
$7.52
$7.87
1-Wochen-Bereich:
$7.28
$9.16
52-Wochen-Spanne:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Vergleichen Sie CYBN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.5756 | 188.40M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.98 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.60 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
538.65 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.97 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Cybin CEO Doug Drysdale: Revolutionizing Depression Treatment - worth.com
Psychedelic Industry Summit: Top CEOs and Investors Unite to Shape $Billion Market Future - Stock Titan
Cybin Provides Corporate Update and Highlights Positive Regulato - GuruFocus
# Cybin begins phase 3 trials for depression treatment CYB003 By Investing.com - Investing.com South Africa
Silicon Valley - FinancialContent
Cybin Advances Phase 3 Program Amid Positive Regulatory Signals - TipRanks
# Cybin begins phase 3 trials for depression treatment CYB003 - Investing.com Australia
Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics - MarketScreener
Should You Buy Polkadot While It's Under $5? - The Globe and Mail
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Business Wire
Prediction: This Company Will Be the Most Valuable AI Stock in 2026 - The Globe and Mail
Billionaire Bill Ackman Just Scooped Up Shares of This Unstoppable Stock - The Globe and Mail
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Per - GuruFocus
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference | CYBN Stock News - GuruFocus
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference - The Globe and Mail
Cybin to Participate in the 2025 Psychedelic Science Conference - GuruFocus
Cybin to Participate in the 2025 Psychedelic Science Conference | CYBN Stock News - GuruFocus
Crypto's hottest new trend: publicly traded companies buying bunches of bitcoin - The Globe and Mail
(CYBN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Cybin, Inc: The Strategic Approach to Formulating a Successful CYB003 Launch - Smartkarma
Cybin (CYBN) Gains Positive Outlook from Lucid Capital | CYBN St - GuruFocus
Market Analysis: June 6th, 2025 - The Globe and Mail
lucid capital markets initiates buy rating on cybin stock - Investing.com Australia
lucid capital markets initiates buy rating on cybin stock By Investing.com - Investing.com South Africa
Cybin (CYBN) Gains Positive Outlook from Lucid Capital | CYBN Stock News - GuruFocus
Cybin secures U.S. patent for program targeting generalized Anxiety disorder and depression - Proactive Investors
Cybin, Inc.The Strategic Approach to Formulating a Successful CYB003 Launch - Smartkarma
Massive News for DraftKings Stock Investors - The Globe and Mail
Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder - BioSpace
Cybin secures patent for anxiety disorder treatment CYB004 - Investing.com
Cybin Granted Additional US Patent for Potential Anxiety Disorder Treatments - MarketScreener
Cybin secures patent for anxiety disorder treatment CYB004 By Investing.com - Investing.com Canada
Cybin Secures U.S. Patent for CYB004 Program in Anxiety Disorder Treatment - TipRanks
Cybin (CYBN) Secures U.S. Patent for CYB004 Program | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting its CYB004 Pro - GuruFocus
Will Blue Chip UPS Deliver for Shareholders? - The Globe and Mail
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Transcript : Cybin Inc.Special Call - marketscreener.com
(CYBN) Proactive Strategies - news.stocktradersdaily.com
Prediction: Dogecoin Will Plummet to New Lows by the End of the Year. Here's Why. - The Globe and Mail
Cboe Canada Single Security - Cboe Global Markets
Billionaire CEO Jamie Dimon Just Delivered a Stark Warning to the Market. Here Are 3 Things Investors Should Do. - The Globe and Mail
This Chinese Robotaxi Stock Could Be an Even Better Buy Than Tesla Before June - The Globe and Mail
Cybin CEO to Discuss Strategic Advances at Upcoming Fireside Chat - TipRanks
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 - BioSpace
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 | CYBN Stock News - GuruFocus
Cybin CEO Reveals Latest on Phase 3 Psychedelics Program and FDA Developments in Exclusive Analyst Chat - Stock Titan
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.18%
Kapitalisierung:
|
Volumen (24h):